<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="review-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">lvrach</journal-id><journal-title-group><journal-title xml:lang="ru">Лечащий Врач</journal-title><trans-title-group xml:lang="en"><trans-title>Lechaschi Vrach</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1560-5175</issn><issn pub-type="epub">2687-1181</issn><publisher><publisher-name>ООО «Издательство "Открытые системы"»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.51793/OS.2026.29.5.004</article-id><article-id custom-type="elpub" pub-id-type="custom">lvrach-1611</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ГАСТРОЭНТЕРОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>GASTROENTEROLOGY</subject></subj-group></article-categories><title-group><article-title>СРК-подобные симптомы при воспалительных заболеваниях кишечника: клиническая необходимость или терминологический компромисс?</article-title><trans-title-group xml:lang="en"><trans-title>IBS-like symptoms in inflammatory bowel diseases: clinical necessity or a terminological compromise?</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6151-2021</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бакулин</surname><given-names>И. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Bakulin</surname><given-names>I. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Бакулин Игорь Геннадьевич, д.м.н., профессор, главный внештатный  специалист-терапевт Министерства здравоохранения Российской Федерации по Северо-Западному федеральному округу Российской Федерации, главный внештатный специалист-гастроэнтеролог Ленинградской области, директор Института терапии, заведующий кафедрой пропедевтики внутренних болезней, гастроэнтерологии и диетологии им. С. М. Рысса,</p><p>195067, Санкт-Петербург, Пискаревский пр., 47</p></bio><bio xml:lang="en"><p>Igor G. Bakulin, Dr. of Sci. (Med.), Professor, Chief Non-staff Specialist in Internal Medicine of the Ministry of Health of the Russian Federation for the North-Western Federal District, Chief Nonstaff Gastroenterologist of the Leningrad Region, Director of the Institute of Therapy, Head of the Department of Propedeutics of Internal Diseases, Gastroenterology and Dietology named after S. M. Ryss,</p><p>47 Piskarevsky ave., Saint Petersburg, 195067</p></bio><email xlink:type="simple">igbakulin@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4719-3973</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Акишина</surname><given-names>Ю. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Akishina</surname><given-names>Yu. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Акишина Юлия Андреевна, ординатор кафедры пропедевтики внутренних болезней, гастроэнтерологии и диетологии им. С. М. Рысса, </p><p>195067, Санкт-Петербург, Пискаревский пр., 47</p></bio><bio xml:lang="en"><p>Yulia A. Akishina, Resident of the Department of Propedeutics of Internal Diseases, Gastroenterology and Dietology named after S. M. Ryss,</p><p>47 Piskarevsky ave., Saint Petersburg, 195067</p></bio><email xlink:type="simple">akishina220500@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Северо-Западный государственный медицинский университет имени И. И. Мечникова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>I. I. Mechnikov Northwestern State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>08</day><month>06</month><year>2026</year></pub-date><volume>0</volume><issue>5</issue><fpage>34</fpage><lpage>40</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Бакулин И.Г., Акишина Ю.А., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Бакулин И.Г., Акишина Ю.А.</copyright-holder><copyright-holder xml:lang="en">Bakulin I.G., Akishina Y.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.lvrach.ru/jour/article/view/1611">https://journal.lvrach.ru/jour/article/view/1611</self-uri><abstract><sec><title>Введение</title><p>Введение. Несмотря на наличие эффективных терапевтических стратегий, направленных на индукцию и поддержание ремиссии воспалительных заболеваний кишечника, у части пациентов имеют место персистирующие гастроинтестинальные симптомы: рецидивирующий абдоминальный болевой синдром, изменение частоты и/или консистенции стула, что нередко трактуется как симптомы, сходные с проявлениями синдрома раздраженного кишечника (СРК). Учитывая гетерогенность возможных причин гастроинтестинальных нарушений и отсутствие валидированных диагностических критериев для данной популяции пациентов, использование термина «СРК-подобные симптомы» при воспалительных заболеваниях кишечника остается предметом дискуссий. Длительно сохраняющиеся симптомы со стороны желудочно-кишечного тракта, а в некоторых случаях и системные проявления могут быть вызваны широким спектром этиологических факторов, включая синдром избыточного бактериального роста, мальабсорбцию желчных кислот и/или олиго-/моносахаридов, экзокринную недостаточность поджелудочной железы, глютен-ассоциированные состояния, эозинофильные гастроинтестинальные заболевания, синдром активации тучных клеток, а также состояния, не связанные с непосредственным вовлечением желудочно-кишечного тракта, в частности, эндометриоз и спаечную болезнь.</p></sec><sec><title>Заключение</title><p>Заключение. Учитывая сказанное выше, использование термина «СРК-подобные симптомы» представляется оправданным в случаях, когда у пациента с воспалительными заболеваниями кишечника достигнута гистологическая ремиссия, а сохраняющиеся гастроинтестинальные симптомы обусловлены расстройствами оси «кишечник – мозг». Применение вышеуказанного термина целесообразно при условии исключения иных причин, способных объяснить клинические проявления как со стороны желудочно-кишечного тракта, так и за его пределами.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Background</title><p>Background. Despite the availability of effective therapeutic strategies aimed at inducing and maintaining remission in inflammatory bowel disease, a subset of patients continues to experience persistent gastrointestinal symptoms, including recurrent abdominal pain and alterations in stool frequency and/or consistency. These manifestations are often interpreted as resembling symptoms of irritable bowel syndrome (IBS). Given the heterogeneity of potential etiologies underlying gastrointestinal disturbances and the absence of validated diagnostic criteria for this specific patient population, the use of the term "IBS-like symptoms" in the context of inflammatory bowel disease remains controversial. Persistent gastrointestinal complaints, and in some cases systemic manifestations, may be attributable to a broad spectrum of etiological factors. These include small intestinal bacterial overgrowth, bile acid malabsorption, carbohydrate (oligo- and monosaccharide) malabsorption, exocrine pancreatic insufficiency, gluten-related disorders, eosinophilic gastrointestinal diseases, mast cell activation syndrome, as well as conditions not directly involving the gastrointestinal tract, such as endometriosis and postoperative adhesions.</p></sec><sec><title>Conclusion</title><p>Conclusion. In light of the above, the use of the term "IBS-like symptoms" appears justified only in patients with inflammatory bowel disease who have achieved histological remission and in whom persistent gastrointestinal symptoms are attributable to disorders of the gut-brain axis. The application of this term should be reserved for cases in which alternative causes capable of explaining the clinical manifestations – both gastrointestinal and extraintestinal – have been carefully excluded.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>СРК-подобные симптомы</kwd><kwd>воспалительные заболевания кишечника</kwd><kwd>болезнь Крона</kwd><kwd>язвенный колит</kwd><kwd>расстройства оси «кишечник – мозг»</kwd></kwd-group><kwd-group xml:lang="en"><kwd>IBS-like symptoms</kwd><kwd>inflammatory bowel disease</kwd><kwd>Crohn’s disease</kwd><kwd>ulcerative colitis</kwd><kwd>disorders of gut-brain interaction</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Lim J., Rezaie A. Irritable bowel syndrome-like symptoms in quiescent inflammatory bowel disease: a practical approach to diagnosis and treatment of organic causes. Dig Dis Sci. 2023; 68 (11): 4081-4097. DOI: 10.1007/s10620-023-08095-w.</mixed-citation><mixed-citation xml:lang="en">Lim J., Rezaie A. Irritable bowel syndrome-like symptoms in quiescent inflammatory bowel disease: a practical approach to diagnosis and treatment of organic causes. Dig Dis Sci. 2023; 68 (11): 4081-4097. DOI: 10.1007/s10620-023-08095-w.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Abdalla M. I., Sandler R. S., et al. Prevalence and impact of inflammatory bowel disease-irritable bowel syndrome on patient-reported outcomes in CCFA partners. Inflamm Bowel Dis. 2017; 23: 325-331. DOI: 10.1097/MIB.0000000000001017.</mixed-citation><mixed-citation xml:lang="en">Abdalla M. I., Sandler R. S., et al. Prevalence and impact of inflammatory bowel disease-irritable bowel syndrome on patient-reported outcomes in CCFA partners. Inflamm Bowel Dis. 2017; 23: 325-331. DOI: 10.1097/MIB.0000000000001017.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Ford A. C., Lacy B. E., Talley N. J. Irritable bowel syndrome. N Engl J Med. 2017; 376 (26): 2566-2578.</mixed-citation><mixed-citation xml:lang="en">Ford A. C., Lacy B. E., Talley N. J. Irritable bowel syndrome. N Engl J Med. 2017; 376 (26): 2566-2578.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Aliu A., Bosch D. H. C. A., Keszthelyi D., et al. A practical approach to persistent gastrointestinal symptoms in inflammatory bowel disease in remission. Aliment Pharmacol Ther. 2024; 59 (12): 1470-1488. DOI: 10.1111/apt.17988.</mixed-citation><mixed-citation xml:lang="en">Aliu A., Bosch D. H. C. A., Keszthelyi D., et al. A practical approach to persistent gastrointestinal symptoms in inflammatory bowel disease in remission. Aliment Pharmacol Ther. 2024; 59 (12): 1470-1488. DOI: 10.1111/apt.17988.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Kraimi N., Ross T., Pujo J., et al. The gut microbiome in disorders of gut-brain interaction. Gut Microbes. 2024; 16 (1): 2360233. DOI: 10.1080/19490976.2024.2360233.</mixed-citation><mixed-citation xml:lang="en">Kraimi N., Ross T., Pujo J., et al. The gut microbiome in disorders of gut-brain interaction. Gut Microbes. 2024; 16 (1): 2360233. DOI: 10.1080/19490976.2024.2360233.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Drossman D. A., Hasler W. L. Rome IV – functional GI disorders: disorders of gut-brain interaction. Gastroenterology. 2016; 150 (6): 1257-1261. DOI: 10.1053/j.gastro.2016.03.035.</mixed-citation><mixed-citation xml:lang="en">Drossman D. A., Hasler W. L. Rome IV – functional GI disorders: disorders of gut-brain interaction. Gastroenterology. 2016; 150 (6): 1257-1261. DOI: 10.1053/j.gastro.2016.03.035.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Drossman D. A. Functional gastrointestinal disorders: history, pathophysiology, clinical features, and Rome IV. Gastroenterology. 2016; 150 (6): 1262-1279.e2. DOI: 10.1053/j.gastro.2016.02.032.</mixed-citation><mixed-citation xml:lang="en">Drossman D. A. Functional gastrointestinal disorders: history, pathophysiology, clinical features, and Rome IV. Gastroenterology. 2016; 150 (6): 1262-1279.e2. DOI: 10.1053/j.gastro.2016.02.032.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Mayer E. A., Ryu H. J., Bhatt R. R. The neurobiology of irritable bowel syndrome. Mol Psychiatry. 2023; 28 (4): 1451-1465. DOI: 10.1038/s41380-023-01972-w.</mixed-citation><mixed-citation xml:lang="en">Mayer E. A., Ryu H. J., Bhatt R. R. The neurobiology of irritable bowel syndrome. Mol Psychiatry. 2023; 28 (4): 1451-1465. DOI: 10.1038/s41380-023-01972-w.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Fairbrass K. M., Costantino S. J., et al. Prevalence of irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease in remission: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020; 5 (12): 1053-1062. DOI: 10.1016/S2468-1253(20)30300-9.</mixed-citation><mixed-citation xml:lang="en">Fairbrass K. M., Costantino S. J., et al. Prevalence of irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease in remission: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020; 5 (12): 1053-1062. DOI: 10.1016/S2468-1253(20)30300-9.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Turner D., Ricciuto A., Lewis A., et al. STRIDE-II: selecting therapeutic targets in inflammatory bowel disease. Gastroenterology. 2021; 160 (5): 1570-1583. DOI: 10.1053/j.gastro.2020.12.031.</mixed-citation><mixed-citation xml:lang="en">Turner D., Ricciuto A., Lewis A., et al. STRIDE-II: selecting therapeutic targets in inflammatory bowel disease. Gastroenterology. 2021; 160 (5): 1570-1583. DOI: 10.1053/j.gastro.2020.12.031.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Oka P., Parr H., Barberio B., et al. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020; 5 (10): 908- 917. DOI: 10.1016/S2468-1253(20)30217-X.</mixed-citation><mixed-citation xml:lang="en">Oka P., Parr H., Barberio B., et al. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020; 5 (10): 908- 917. DOI: 10.1016/S2468-1253(20)30217-X.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Barratt S. M., Leeds J. S., Robinson K., et al. Prodromal irritable bowel syndrome and delay in diagnosis of Crohn’s disease. Dig Dis Sci. 2011; 56: 3270-3275.</mixed-citation><mixed-citation xml:lang="en">Barratt S. M., Leeds J. S., Robinson K., et al. Prodromal irritable bowel syndrome and delay in diagnosis of Crohn’s disease. Dig Dis Sci. 2011; 56: 3270-3275.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Fukuba N., Ishihara S., Tada Y., et al. Prevalence of irritable bowel syndrome-like symptoms in ulcerative colitis patients in remission. Scand J Gastroenterol. 2014; 49: 674-680.</mixed-citation><mixed-citation xml:lang="en">Fukuba N., Ishihara S., Tada Y., et al. Prevalence of irritable bowel syndrome-like symptoms in ulcerative colitis patients in remission. Scand J Gastroenterol. 2014; 49: 674-680.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Hoekman D. R., Zeevenhooven J., D’Haens G. R., et al. The prevalence of irritable bowel syndrometype symptoms in inflammatory bowel disease patients in remission. Eur J Gastroenterol Hepatol. 2017; 29: 1086-1090.</mixed-citation><mixed-citation xml:lang="en">Hoekman D. R., Zeevenhooven J., D’Haens G. R., et al. The prevalence of irritable bowel syndrometype symptoms in inflammatory bowel disease patients in remission. Eur J Gastroenterol Hepatol. 2017; 29: 1086-1090.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Henriksen M., Høivik M. L., Jelsness-Jørgensen L. P., et al. Irritable bowel-like symptoms in ulcerative colitis in deep remission. J Crohns Colitis. 2018; 12: 389-393.</mixed-citation><mixed-citation xml:lang="en">Henriksen M., Høivik M. L., JelsnessJørgensen L. P., et al. Irritable bowel-like symptoms in ulcerative colitis in deep remission. J Crohns Colitis. 2018; 12: 389-393.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Perera L. P., Radigan M., Guilday C., et al. IBS symptoms in quiescent inflammatory bowel disease and anxiety/depression. Dig Dis Sci. 2019; 64: 1923-1928.</mixed-citation><mixed-citation xml:lang="en">Perera L. P., Radigan M., Guilday C., et al. IBS symptoms in quiescent inflammatory bowel disease and anxiety/depression. Dig Dis Sci. 2019; 64: 1923-1928.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Nigam G. B., Limdi J. K., Hamdy S., et al. Rome IV functional colorectal disorders in ulcerative colitis. Gut. 2019; 68: A203-A204.</mixed-citation><mixed-citation xml:lang="en">Nigam G. B., Limdi J. K., Hamdy S., et al. Rome IV functional colorectal disorders in ulcerative colitis. Gut. 2019; 68: A203-A204.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Ozer M., Bengi G., Colak R., et al. IBS-like symptoms in inactive IBD using Rome IV criteria. Medicine (Baltimore). 2020; 99: e20067.</mixed-citation><mixed-citation xml:lang="en">Ozer M., Bengi G., Colak R., et al. IBS-like symptoms in inactive IBD using Rome IV criteria. Medicine (Baltimore). 2020; 99: e20067.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Vivinus-Nébot M., Frin-Mathy G., et al. Functional bowel symptoms in quiescent IBD: epithelial barrier disruption. Gut. 2014; 63: 744-752.</mixed-citation><mixed-citation xml:lang="en">Vivinus-Nébot M., Frin-Mathy G., et al. Functional bowel symptoms in quiescent IBD: epithelial barrier disruption. Gut. 2014; 63: 744-752.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Tomita T., Kato Y., Takimoto M., et al. IBS-like symptoms in Japanese patients with inactive IBD. J Neurogastroenterol Motil. 2016; 22: 661-669.</mixed-citation><mixed-citation xml:lang="en">Tomita T., Kato Y., Takimoto M., et al. IBS-like symptoms in Japanese patients with inactive IBD. J Neurogastroenterol Motil. 2016; 22: 661-669.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Olsen B., Opheim R., Kristensen V.A., et al. Symptoms of IBS in remission from IBD: IBSEN III study. J Crohns Colitis. 2024; 18 (Suppl 1): i2055. DOI: 10.1093/ecco-jcc/jjad212.1277.</mixed-citation><mixed-citation xml:lang="en">Olsen B., Opheim R., Kristensen V.A., et al. Symptoms of IBS in remission from IBD: IBSEN III study. J Crohns Colitis. 2024; 18 (Suppl 1): i2055. DOI: 10.1093/ecco-jcc/jjad212.1277.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Colombel J. F., Shin A., Gibson P. R. AGA Clinical Practice Update on functional gastrointestinal symptoms in IBD. Clin Gastroenterol Hepatol. 2019; 17 (3): 380-390.e1. DOI: 10.1016/j.cgh.2018.08.001.</mixed-citation><mixed-citation xml:lang="en">Colombel J. F., Shin A., Gibson P. R. AGA Clinical Practice Update on functional gastrointestinal symptoms in IBD. Clin Gastroenterol Hepatol. 2019; 17 (3): 380-390.e1. DOI: 10.1016/j.cgh.2018.08.001.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Barkun A. N., Love J., Gould M., et al. Bile acid malabsorption in chronic diarrhea. Can J Gastroenterol. 2013; 27 (11): 653-659.</mixed-citation><mixed-citation xml:lang="en">Barkun A. N., Love J., Gould M., et al. Bile acid malabsorption in chronic diarrhea. Can J Gastroenterol. 2013; 27 (11): 653-659.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Pimentel M., Saad R. J., Long M. D., et al. ACG clinical guideline: small intestinal bacterial overgrowth. Am J Gastroenterol. 2020; 115: 165-178. DOI: 10.14309/ajg.0000000000000501.</mixed-citation><mixed-citation xml:lang="en">Pimentel M., Saad R. J., Long M. D., et al. ACG clinical guideline: small intestinal bacterial overgrowth. Am J Gastroenterol. 2020; 115: 165-178. DOI: 10.14309/ajg.0000000000000501.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Lee J. M., Lee K. M., Chung Y. Y., et al. Clinical significance of glucose breath test in IBD. J Gastroenterol Hepatol. 2015; 30: 990-994. DOI: 10.1111/jgh.12908.</mixed-citation><mixed-citation xml:lang="en">Lee J. M., Lee K. M., Chung Y. Y., et al. Clinical significance of glucose breath test in IBD. J Gastroenterol Hepatol. 2015; 30: 990-994. DOI: 10.1111/jgh.12908.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Wanzl J., Grohl K., Kafel A., et al. Impact of small intestinal bacterial overgrowth in patients with inflammatory bowel disease and other gastrointestinal disorders. J Clin Med. 2023; 12 (3): 935. DOI: 10.3390/jcm12030935.</mixed-citation><mixed-citation xml:lang="en">Wanzl J., Grohl K., Kafel A., et al. Impact of small intestinal bacterial overgrowth in patients with inflammatory bowel disease and other gastrointestinal disorders. J Clin Med. 2023; 12 (3): 935. DOI: 10.3390/jcm12030935.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Ghoshal U. C., Yadav A., Fatima B., et al. Small intestinal bacterial overgrowth in inflammatory bowel disease: a case-control study. Indian J Gastroenterol. 2022; 41: 96-103. DOI: 10.1007/s12664-021-01211-6.</mixed-citation><mixed-citation xml:lang="en">Ghoshal U. C., Yadav A., Fatima B., et al. Small intestinal bacterial overgrowth in inflammatory bowel disease: a case-control study. Indian J Gastroenterol. 2022; 41: 96-103. DOI: 10.1007/s12664-021-01211-6.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Shah A., Morrison M., Burger D., et al. Prevalence of small intestinal bacterial overgrowth in inflammatory bowel disease: a systematic review and meta-analysis. Aliment Pharmacol Ther. 2019; 49 (6): 624-635. DOI: 10.1111/apt.15173.</mixed-citation><mixed-citation xml:lang="en">Shah A., Morrison M., Burger D., et al. Prevalence of small intestinal bacterial overgrowth in inflammatory bowel disease: a systematic review and meta-analysis. Aliment Pharmacol Ther. 2019; 49 (6): 624-635. DOI: 10.1111/apt.15173.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Min Y. W., Rezaie A., Pimentel M. Bile acid and gut microbiota in irritable bowel syndrome. J Neurogastroenterol Motil. 2022; 28: 549-561. DOI: 10.5056/jnm22129.</mixed-citation><mixed-citation xml:lang="en">Min Y. W., Rezaie A., Pimentel M. Bile acid and gut microbiota in irritable bowel syndrome. J Neurogastroenterol Motil. 2022; 28: 549-561. DOI: 10.5056/jnm22129.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Barrett J. S., Irving P. M., Shepherd S. J., et al. Comparison of fructose and lactose malabsorption across chronic intestinal disorders. Aliment Pharmacol Ther. 2009; 30: 165-174. DOI: 10.1111/j.1365-2036.2009.04018.x.</mixed-citation><mixed-citation xml:lang="en">Barrett J. S., Irving P. M., Shepherd S. J., et al. Comparison of fructose and lactose malabsorption across chronic intestinal disorders. Aliment Pharmacol Ther. 2009; 30: 165-174. DOI: 10.1111/j.1365-2036.2009.04018.x.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Ramos L. R., Sachar D. B., DiMaio C. J., et al. Inflammatory bowel disease and pancreatitis: a review. J Crohns Colitis. 2016; 10: 95-104. DOI: 10.1093/ecco-jcc/jjv153.</mixed-citation><mixed-citation xml:lang="en">Ramos L. R., Sachar D. B., DiMaio C. J., et al. Inflammatory bowel disease and pancreatitis: a review. J Crohns Colitis. 2016; 10: 95-104. DOI: 10.1093/ecco-jcc/jjv153.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Sikkens E. C. M., Cahen D. L., Koch A. D., et al. Prevalence of fat-soluble vitamin deficiencies and decreased bone mass in chronic pancreatitis. Pancreatology. 2013; 13: 238-242.</mixed-citation><mixed-citation xml:lang="en">Sikkens E. C. M., Cahen D. L., Koch A. D., et al. Prevalence of fat-soluble vitamin deficiencies and decreased bone mass in chronic pancreatitis. Pancreatology. 2013; 13: 238-242.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Shintakuya R., Uemura K., Murakami Y., et al. Sarcopenia is associated with pancreatic exocrine insufficiency in pancreatic disease. Pancreatology. 2017; 17: 70-75.</mixed-citation><mixed-citation xml:lang="en">Shintakuya R., Uemura K., Murakami Y., et al. Sarcopenia is associated with pancreatic exocrine insufficiency in pancreatic disease. Pancreatology. 2017; 17: 70-75.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">De la Iglesia D., Vallejo-Senra N., López-López A., et al. Effect of pancreatic exocrine and endocrine insufficiency on cardiovascular events in chronic pancreatitis. Pancreatology. 2018; 18.</mixed-citation><mixed-citation xml:lang="en">De la Iglesia D., Vallejo-Senra N., López-López A., et al. Effect of pancreatic exocrine and endocrine insufficiency on cardiovascular events in chronic pancreatitis. Pancreatology. 2018; 18.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Maconi G., Dominici R., Molteni M., et al. Prevalence of pancreatic insufficiency in inflammatory bowel diseases assessed by fecal elastase-1. Dig Dis Sci. 2008; 53: 262-270. DOI: 10.1007/s10620-007-9852-y.</mixed-citation><mixed-citation xml:lang="en">Maconi G., Dominici R., Molteni M., et al. Prevalence of pancreatic insufficiency in inflammatory bowel diseases assessed by fecal elastase-1. Dig Dis Sci. 2008; 53: 262-270. DOI: 10.1007/s10620-007-9852-y.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Pinto-Sanchez M. I., Seiler C. L., Santesso N., et al. Association between inflammatory bowel diseases and celiac disease: a systematic review and meta-analysis. Gastroenterology. 2020; 159 (3): 884-903.e31. DOI: 10.1053/j.gastro.2020.05.007.</mixed-citation><mixed-citation xml:lang="en">Pinto-Sanchez M. I., Seiler C. L., Santesso N., et al. Association between inflammatory bowel diseases and celiac disease: a systematic review and meta-analysis. Gastroenterology. 2020; 159 (3): 884-903.e31. DOI: 10.1053/j.gastro.2020.05.007.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Lazzano P., Fracas E., Nandi N., et al. Extraintestinal complications of celiac disease: treatment considerations. Expert Rev Gastroenterol Hepatol. 2024; 18 (12): 761-777. DOI: 10.1080/17474124.2024.2443053.</mixed-citation><mixed-citation xml:lang="en">Lazzano P., Fracas E., Nandi N., et al. Extraintestinal complications of celiac disease: treatment considerations. Expert Rev Gastroenterol Hepatol. 2024; 18 (12): 761-777. DOI: 10.1080/17474124.2024.2443053.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Cardenas-Torres F. I., Cabrera-Chavez F., Figueroa-Salcido O. G., et al. Non-celiac gluten sensitivity: an update. Medicina (Kaunas). 2021; 57: 526. DOI: 10.3390/medicina57060526.</mixed-citation><mixed-citation xml:lang="en">Cardenas-Torres F. I., Cabrera-Chavez F., Figueroa-Salcido O. G., et al. Non-celiac gluten sensitivity: an update. Medicina (Kaunas). 2021; 57: 526. DOI: 10.3390/medicina57060526.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Naik R. D., Seidner D. L., Adams D. W. Nutritional considerations in celiac disease and nonceliac gluten sensitivity. Gastroenterol Clin North Am. 2018; 47 (1): 139-154. DOI: 10.1016/j.gtc.2017.09.006.</mixed-citation><mixed-citation xml:lang="en">Naik R. D., Seidner D. L., Adams D. W. Nutritional considerations in celiac disease and nonceliac gluten sensitivity. Gastroenterol Clin North Am. 2018; 47 (1): 139-154. DOI: 10.1016/j.gtc.2017.09.006.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Volta U., Caio G., De Giorgio R., et al. Non-celiac gluten sensitivity: a work-in-progress entity. Best Pract Res Clin Gastroenterol. 2015; 29: 477- 491. DOI: 10.1016/j.bpg.2015.04.006.</mixed-citation><mixed-citation xml:lang="en">Volta U., Caio G., De Giorgio R., et al. Non-celiac gluten sensitivity: a work-in-progress entity. Best Pract Res Clin Gastroenterol. 2015; 29: 477- 491. DOI: 10.1016/j.bpg.2015.04.006.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Di Sabatino A., Volta U., Salvatore C., et al. Small amounts of gluten in suspected nonceliac gluten sensitivity: a randomized trial. Clin Gastroenterol Hepatol. 2015; 13 (9): 1604-1612.e3.</mixed-citation><mixed-citation xml:lang="en">Di Sabatino A., Volta U., Salvatore C., et al. Small amounts of gluten in suspected nonceliac gluten sensitivity: a randomized trial. Clin Gastroenterol Hepatol. 2015; 13 (9): 1604-1612.e3.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Dellon E. S., Gonsalves N., Abonia J. P., et al. International consensus recommendations for eosinophilic gastrointestinal disease nomenclature. Clin Gastroenterol Hepatol. 2022; 20: 2474-2484.e3. DOI: 10.1016/j.cgh.2022.02.017.</mixed-citation><mixed-citation xml:lang="en">Dellon E. S., Gonsalves N., Abonia J. P., et al. International consensus recommendations for eosinophilic gastrointestinal disease nomenclature. Clin Gastroenterol Hepatol. 2022; 20: 2474-2484.e3. DOI: 10.1016/j.cgh.2022.02.017.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Shoda T., Collins M. H., Rochman M., et al. Evaluating eosinophilic colitis as a unique disease using colonic molecular profiles. Gastroenterology. 2022; 162 (6): 1635-1649. DOI: 10.1053/j.gastro.2022.01.022</mixed-citation><mixed-citation xml:lang="en">Shoda T., Collins M. H., Rochman M., et al. Evaluating eosinophilic colitis as a unique disease using colonic molecular profiles. Gastroenterology. 2022; 162 (6): 1635-1649. DOI: 10.1053/j.gastro.2022.01.022</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Walker M. M., Potter M., Talley N. J. Eosinophilic gastroenteritis and other eosinophilic gut diseases. Lancet Gastroenterol Hepatol. 2018; 3: 271-280. DOI: 10.1016/S2468-1253(18)30005-0.</mixed-citation><mixed-citation xml:lang="en">Walker M. M., Potter M., Talley N. J. Eosinophilic gastroenteritis and other eosinophilic gut diseases. Lancet Gastroenterol Hepatol. 2018; 3: 271-280. DOI: 10.1016/S2468-1253(18)30005-0.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Tozlu M., Cash B., Younes M., et al. Dilemma in post-IBD patients with IBS-D symptoms. Expert Rev Gastroenterol Hepatol. 2021; 15: 5-8. DOI: 10.1080/17474124.2021.1829469.</mixed-citation><mixed-citation xml:lang="en">Tozlu M., Cash B., Younes M., et al. Dilemma in post-IBD patients with IBS-D symptoms. Expert Rev Gastroenterol Hepatol. 2021; 15: 5-8. DOI: 10.1080/17474124.2021.1829469.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Pineton de Chambrun G., Gonzalez F., et al. Natural history of eosinophilic gastroenteritis. Clin Gastroenterol Hepatol. 2011; 9 (11): 950-956. e1. DOI: 10.1016/j.cgh.2011.07.017.</mixed-citation><mixed-citation xml:lang="en">Pineton de Chambrun G., Gonzalez F., et al. Natural history of eosinophilic gastroenteritis. Clin Gastroenterol Hepatol. 2011; 9 (11): 950-956. e1. DOI: 10.1016/j.cgh.2011.07.017.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Abou Rached A., El Hajj W. Eosinophilic gastroenteritis: approach to diagnosis and management. World J Gastrointest Pharmacol Ther. 2016; 7 (4): 513-523. DOI: 10.4292/wjgpt.v7.i4.513.</mixed-citation><mixed-citation xml:lang="en">Abou Rached A., El Hajj W. Eosinophilic gastroenteritis: approach to diagnosis and management. World J Gastrointest Pharmacol Ther. 2016; 7 (4): 513-523. DOI: 10.4292/wjgpt.v7.i4.513.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Weiler C. R., Austen K. F., Akin C., et al. Mast cell activation syndrome diagnosis and management. J Allergy Clin Immunol. 2019; 144 (4): 883-896.</mixed-citation><mixed-citation xml:lang="en">Weiler C. R., Austen K. F., Akin C., et al. Mast cell activation syndrome diagnosis and management. J Allergy Clin Immunol. 2019; 144 (4): 883-896.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Boeckxstaens G. Mast cells and inflammatory bowel disease. Curr Opin Pharmacol. 2015; 25: 45-49. DOI: 10.1016/j.coph.2015.11.005.</mixed-citation><mixed-citation xml:lang="en">Boeckxstaens G. Mast cells and inflammatory bowel disease. Curr Opin Pharmacol. 2015; 25: 45-49. DOI: 10.1016/j.coph.2015.11.005.</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Fan L., Wong M., Fan X. S., et al. Intramucosal mast cells in IBS vs IBD in remission. J Clin Gastroenterol. 2021; 55: 244-249. DOI: 10.1097/MCG.0000000000001394.</mixed-citation><mixed-citation xml:lang="en">Fan L., Wong M., Fan X. S., et al. Intramucosal mast cells in IBS vs IBD in remission. J Clin Gastroenterol. 2021; 55: 244-249. DOI: 10.1097/MCG.0000000000001394.</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Gelbmann C. M., Mestermann S., Gross V., et al. Strictures in Crohn's disease are characterized by accumulation of mast cells. Gut. 1999; 45: 210-217. DOI: 10.1136/gut.45.2.210.</mixed-citation><mixed-citation xml:lang="en">Gelbmann C. M., Mestermann S., Gross V., et al. Strictures in Crohn's disease are characterized by accumulation of mast cells. Gut. 1999; 45: 210-217. DOI: 10.1136/gut.45.2.210.</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Afrin L. B., Ackerley M. B., Bluestein L. S., et al. Diagnosis of mast cell activation syndrome: a global consensus-2. Diagnosis (Berl). 2020; 8 (2): 137-152. DOI: 10.1515/dx-2020-0005.</mixed-citation><mixed-citation xml:lang="en">Afrin L. B., Ackerley M. B., Bluestein L. S., et al. Diagnosis of mast cell activation syndrome: a global consensus-2. Diagnosis (Berl). 2020; 8 (2): 137-152. DOI: 10.1515/dx-2020-0005.</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Beckers A. B., Keszthelyi D., Fikree A., et al. Gastrointestinal disorders in joint hypermobility syndrome/Ehlers-Danlos syndrome. Neurogastroenterol Motil. 2017; 29: e13013. DOI: 10.1111/nmo.13013.</mixed-citation><mixed-citation xml:lang="en">Beckers A. B., Keszthelyi D., Fikree A., et al. Gastrointestinal disorders in joint hypermobility syndrome/Ehlers-Danlos syndrome. Neurogastroenterol Motil. 2017; 29: e13013. DOI: 10.1111/nmo.13013.</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">DiBaise J. K., Harris L. A., Goodman B. Postural tachycardia syndrome and the GI tract. Am J Gastroenterol. 2018; 113: 1458-1467. DOI: 10.1038/s41395-018-0215-4.</mixed-citation><mixed-citation xml:lang="en">DiBaise J. K., Harris L. A., Goodman B. Postural tachycardia syndrome and the GI tract. Am J Gastroenterol. 2018; 113: 1458-1467. DOI: 10.1038/s41395-018-0215-4.</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Yu V., McHenry N., Proctor S., et al. Endometriosis for gastroenterologists. Dig Dis Sci. 2023. DOI: 10.1007/s10620-022-07674-7.</mixed-citation><mixed-citation xml:lang="en">Yu V., McHenry N., Proctor S., et al. Endometriosis for gastroenterologists. Dig Dis Sci. 2023. DOI: 10.1007/s10620-022-07674-7.</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Chiaffarino F., Cipriani S., Ricci E., et al. Endometriosis and inflammatory bowel disease: a systematic review. Eur J Obstet Gynecol Reprod Biol. 2020; 252: 246-251. DOI: 10.1016/j.ejogrb.2020.06.051.</mixed-citation><mixed-citation xml:lang="en">Chiaffarino F., Cipriani S., Ricci E., et al. Endometriosis and inflammatory bowel disease: a systematic review. Eur J Obstet Gynecol Reprod Biol. 2020; 252: 246-251. DOI: 10.1016/j.ejogrb.2020.06.051.</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Young S., Burns M. K., DiFrancesco L., et al. Diagnostic and treatment guidelines for gastrointestinal endometriosis. J Turk Ger Gynecol Assoc. 2017; 18: 200-209. DOI: 10.4274/jtgga.2017.0143.</mixed-citation><mixed-citation xml:lang="en">Young S., Burns M. K., DiFrancesco L., et al. Diagnostic and treatment guidelines for gastrointestinal endometriosis. J Turk Ger Gynecol Assoc. 2017; 18: 200-209. DOI: 10.4274/jtgga.2017.0143.</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Veeraswamy A., Lewis M., Mann A., et al. Extragenital endometriosis. Clin Obstet Gynecol. 2010; 53: 449-466.</mixed-citation><mixed-citation xml:lang="en">Veeraswamy A., Lewis M., Mann A., et al. Extragenital endometriosis. Clin Obstet Gynecol. 2010; 53: 449-466.</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Parker M. C., Wilson M. S., Menzies D., et al. The SCAR-3 study: adhesion-related readmission risk. Colorectal Dis. 2005; 7: 551-558. DOI: 10.1111/j.1463-1318.2005.00857.x.</mixed-citation><mixed-citation xml:lang="en">Parker M. C., Wilson M. S., Menzies D., et al. The SCAR-3 study: adhesion-related readmission risk. Colorectal Dis. 2005; 7: 551-558. DOI: 10.1111/j.1463-1318.2005.00857.x.</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Moris D., Chakedis J., Rahnemai-Azar A. A., et al. Postoperative abdominal adhesions. J Gastrointest Surg. 2017; 21 (10): 1713-1722. DOI: 10.1007/s11605-017-3488-9.</mixed-citation><mixed-citation xml:lang="en">Moris D., Chakedis J., Rahnemai-Azar A. A., et al. Postoperative abdominal adhesions. J Gastrointest Surg. 2017; 21 (10): 1713-1722. DOI: 10.1007/s11605-017-3488-9.</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">Rezaie A., Gu P., Kaplan G. G., et al. Dyssynergic defecation in inflammatory bowel disease. Inflamm Bowel Dis. 2018; 24 (5): 1065-1073. DOI: 10.1093/ibd/izx095.</mixed-citation><mixed-citation xml:lang="en">Rezaie A., Gu P., Kaplan G. G., et al. Dyssynergic defecation in inflammatory bowel disease. Inflamm Bowel Dis. 2018; 24 (5): 1065-1073. DOI: 10.1093/ibd/izx095.</mixed-citation></citation-alternatives></ref><ref id="cit62"><label>62</label><citation-alternatives><mixed-citation xml:lang="ru">Quinn K. P., Tse C. S., Lightner A. L., et al. Nonrelaxing pelvic floor dysfunction after ileal pouch-anal anastomosis. Clin Gastroenterol Hepatol. 2017; 15: 1242-1247. DOI: 10.1016/j.cgh.2017.02.024.</mixed-citation><mixed-citation xml:lang="en">Quinn K. P., Tse C. S., Lightner A. L., et al. Nonrelaxing pelvic floor dysfunction after ileal pouch-anal anastomosis. Clin Gastroenterol Hepatol. 2017; 15: 1242-1247. DOI: 10.1016/j.cgh.2017.02.024.</mixed-citation></citation-alternatives></ref><ref id="cit63"><label>63</label><citation-alternatives><mixed-citation xml:lang="ru">Coffin B., Duboc H. Persistent abdominal pain beyond irritable bowel syndrome. Aliment Pharmacol Ther. 2022; 56 (3): 419-435. DOI: 10.1111/apt.17064.</mixed-citation><mixed-citation xml:lang="en">Coffin B., Duboc H. Persistent abdominal pain beyond irritable bowel syndrome. Aliment Pharmacol Ther. 2022; 56 (3): 419-435. DOI: 10.1111/apt.17064.</mixed-citation></citation-alternatives></ref><ref id="cit64"><label>64</label><citation-alternatives><mixed-citation xml:lang="ru">Farmer A. D., Gallagher J., Bruckner-Holt C., et al. Narcotic bowel syndrome. Lancet Gastroenterol Hepatol. 2017; 2 (5): 361-368. DOI: 10.1016/ S2468-1253(16)30217-5.</mixed-citation><mixed-citation xml:lang="en">Farmer A. D., Gallagher J., Bruckner-Holt C., et al. Narcotic bowel syndrome. Lancet Gastroenterol Hepatol. 2017; 2 (5): 361-368. DOI: 10.1016/ S2468-1253(16)30217-5.</mixed-citation></citation-alternatives></ref><ref id="cit65"><label>65</label><citation-alternatives><mixed-citation xml:lang="ru">Jharap B., Seinen M. L., de Boer N. K., et al. Thiopurine therapy in inflammatory bowel disease. Inflamm Bowel Dis. 2010; 16 (9): 1541-1549. DOI: 10.1002/ibd.21221.</mixed-citation><mixed-citation xml:lang="en">Jharap B., Seinen M. L., de Boer N. K., et al. Thiopurine therapy in inflammatory bowel disease. Inflamm Bowel Dis. 2010; 16 (9): 1541-1549. DOI: 10.1002/ibd.21221.</mixed-citation></citation-alternatives></ref><ref id="cit66"><label>66</label><citation-alternatives><mixed-citation xml:lang="ru">Philpott H. L., Nandurkar S., Lubel J., et al. Druginduced gastrointestinal disorders. Postgrad Med J. 2014; 90 (1065): 411-419. DOI: 10.1136/postgradmedj-2013-100316</mixed-citation><mixed-citation xml:lang="en">Philpott H. L., Nandurkar S., Lubel J., et al. Druginduced gastrointestinal disorders. Postgrad Med J. 2014; 90 (1065): 411-419. DOI: 10.1136/postgradmedj-2013-100316</mixed-citation></citation-alternatives></ref><ref id="cit67"><label>67</label><citation-alternatives><mixed-citation xml:lang="ru">Jain V., Pitchumoni C. S. Gastrointestinal side effects of prescription medications in older adults. J Clin Gastroenterol. 2009; 43 (2): 103-110. DOI: 10.1097/MCG.0b013e31818f9227.</mixed-citation><mixed-citation xml:lang="en">Jain V., Pitchumoni C. S. Gastrointestinal side effects of prescription medications in older adults. J Clin Gastroenterol. 2009; 43 (2): 103-110. DOI: 10.1097/MCG.0b013e31818f9227.</mixed-citation></citation-alternatives></ref><ref id="cit68"><label>68</label><citation-alternatives><mixed-citation xml:lang="ru">Shian B., Larson S. T. Abdominal wall pain: evaluation and treatment. Am Fam Physician. 2018; 98 (7): 429-436.</mixed-citation><mixed-citation xml:lang="en">Shian B., Larson S. T. Abdominal wall pain: evaluation and treatment. Am Fam Physician. 2018; 98 (7): 429-436.</mixed-citation></citation-alternatives></ref><ref id="cit69"><label>69</label><citation-alternatives><mixed-citation xml:lang="ru">Jagt J. Z., Pothof C. D., Buiter H. J. C., et al. Adverse events of thiopurine therapy in pediatric IBD. Dig Dis Sci. 2022; 67 (1): 241-251. DOI: 10.1007/s10620-021-06836-3.</mixed-citation><mixed-citation xml:lang="en">Jagt J. Z., Pothof C. D., Buiter H. J. C., et al. Adverse events of thiopurine therapy in pediatric IBD. Dig Dis Sci. 2022; 67 (1): 241-251. DOI: 10.1007/s10620-021-06836-3.</mixed-citation></citation-alternatives></ref><ref id="cit70"><label>70</label><citation-alternatives><mixed-citation xml:lang="ru">Moran G. W., Dubeau M. F., Kaplan G. G., et al. Clinical predictors of thiopurine-related adverse events in Crohn's disease. World J Gastroenterol. 2015; 21 (25): 7795-7804. DOI: 10.3748/wjg.v21.i25.7795.</mixed-citation><mixed-citation xml:lang="en">Moran G. W., Dubeau M. F., Kaplan G. G., et al. Clinical predictors of thiopurine-related adverse events in Crohn's disease. World J Gastroenterol. 2015; 21 (25): 7795-7804. DOI: 10.3748/wjg.v21.i25.7795.</mixed-citation></citation-alternatives></ref><ref id="cit71"><label>71</label><citation-alternatives><mixed-citation xml:lang="ru">Zudeh G., Franca R., Stocco G., et al. Biomarkers for gastrointestinal adverse events related to thiopurine therapy. World J Gastroenterol. 2021; 27 (38): 6348-6356. DOI: 10.3748/wjg.v27.i38.6348.</mixed-citation><mixed-citation xml:lang="en">Zudeh G., Franca R., Stocco G., et al. Biomarkers for gastrointestinal adverse events related to thiopurine therapy. World J Gastroenterol. 2021; 27 (38): 6348-6356. DOI: 10.3748/wjg.v27.i38.6348.</mixed-citation></citation-alternatives></ref><ref id="cit72"><label>72</label><citation-alternatives><mixed-citation xml:lang="ru">Groeger D., O’Mahony L., Murphy E. F., Bourke J. F., Dinan T. G., Kiely B., et al. Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut. Gut Microbes. 2013; 4 (4): 325-339. DOI: 10.4161/gmic.25487.</mixed-citation><mixed-citation xml:lang="en">Groeger D., O’Mahony L., Murphy E. F., Bourke J. F., Dinan T. G., Kiely B., et al. Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut. Gut Microbes. 2013; 4 (4): 325-339. DOI: 10.4161/gmic.25487.</mixed-citation></citation-alternatives></ref><ref id="cit73"><label>73</label><citation-alternatives><mixed-citation xml:lang="ru">Maslennikov R., Gosteeva E., Ananeva V., Korshunova L., Kravtsowa A., Poluektova E., et al. Strain-specific systematic review with meta-analysis of probiotics efficacy in the treatment of irritable bowel syndrome. J Clin Med. 2026; 15: 1152. DOI: 10.3390/jcm15031152.</mixed-citation><mixed-citation xml:lang="en">Maslennikov R., Gosteeva E., Ananeva V., Korshunova L., Kravtsowa A., Poluektova E., et al. Strain-specific systematic review with meta-analysis of probiotics efficacy in the treatment of irritable bowel syndrome. J Clin Med. 2026; 15: 1152. DOI: 10.3390/jcm15031152.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
